Investigating Bruton Tyrosine Kinase Inhibition on B-Cell and Monocyte Phenotype and Function in Multiple Sclerosis
Year: 2026
Type: article
Abstract: Background and Objectives Bruton tyrosine kinase inhibitors (BTKis) are emerging therapies for multiple sclerosis (MS) that target BTK signaling in B cells and myeloid cells in both the periphery and CNS. While BTKi mechanisms are well characterized in B cells, their direct effects on disease-relevant monocyte subsets remain incompletely understood, particularly across relapsing and progressive MS. This study aimed to determine how BTK inhibition modulates B-cell and monocyte subset phenotype and function in treatment-naïve relapsing and progressive MS. Methods This experimental study used peripheral blood mononuclear cells (PBMCs) isolated from treatment-naïve individuals with relapsing-remitting or progressive MS and non-MS controls. PBMCs were treated with the BTK inhibitors tolebrutinib or evobrutinib before stimulation. Outcomes included BTK activation (phosphorylated BTK [pBTK]/BTK), cytokine production, and immune-cell phenotypes assessed by ELISA, flow cytometry, and intracellular staining. Neurofilament light (NfL) and inflammatory mediators were quantified as markers of neurodegeneration and immune activation. Small RNA sequencing was performed to identify microRNAs and pathways associated with BTKi-mediated effects. Linear regression analyses were used to assess associations between BTK activation and biomarker levels. Results In total, PBMCs were assayed from 78 individuals (mean age 47 years, 72% female) and grouped according to disease subtype and/or clinical status. In MS, tolebrutinib treatment reduced overall pBTK/BTK levels (95% CI 1.33–1.50; p < 0.0001), in addition to decreasing tumor necrosis factor (TNF) (95% CI 1.45–2.02; p < 0.0001) and interleukin (IL)-12p40 (95% CI 1.62–2.26; p < 0.0001), while increasing IL-10 (95% CI 0.70–0.88; p < 0.0001) in CD14 mid CD16 high monocytes. Similar effects occurred in B cells, with variations related to disease activity and MS subtypes. Using linear regression, individual pBTK/BTK ratios were associated with levels of neurodegenerative and inflammatory markers, including NfL (95% CI 3.36–5.43; p < 0.0001), CXCL10 (95% CI 38.00–82.64; p < 0.0001), TNF (95% CI 60.39–84.78; p < 0.0001), and IL-12 (95% CI 35.13–47.00; p < 0.0001). Small RNASeq revealed differential microRNA regulation in relapsing vs progressive disease. Discussion Overall, our study indicates that BTKis exert cell type–specific immunomodulatory effects on both B cells and disease-relevant monocyte subsets, contributing to their mechanism of action and therapeutic efficacy in relapsing and progressive MS. Defining how these BTK-dependent immune mechanisms translate in vivo will be essential for linking peripheral immune modulation to disease progression and optimizing BTKi-based therapeutic strategies in MS.
Source: Neurology Open Access
Institution: Memorial University of Newfoundland
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: multiple sclerosis, BTK inhibitors, tolebrutinib, evobrutinib, B cells, monocytes, CD14+CD16+ monocytes, BTK phosphorylation, cytokine production, neurofilament light chain, neurodegeneration, microRNA, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, treatment-naive patients
Open Access status: diamond
OpenAlex ID: W7204925762
